HOPO Therapeutics
HOPO Therapeutics
Home
About
Company
People
Careers
FAQ
Our Focus Areas
Radiological Hazards
Lead Poisoning
Metals in Medicine
Our Science
Discovery & Development
HOPO-101
Publications
News
Contact
Intestinal absorption
In Vitro Metabolism and Stability of the Actinide Chelating Agent 3,4,3-LI(1,2-HOPO)
The hydroxypyridinonate ligand 3,4,3-LI(1,2-HOPO) is currently under development for radionuclide chelation therapy. The preclinical characterization of this highly promising ligand comprised the evaluation of its in vitro properties, including …
Cite
×